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Osteoarthritis of the hip: An overview
Abstract
Osteoarthritis, as the most common form of arthritis, affects predomi-
nantly middle-aged and elderly population worldwide. This chronic, degen-
erative, progressive and multifactorial joint disease can affect different joints 
in the body. One of the most commonly affected joints with osteoarthritis is 
the hip joint. Hip osteoarthritis is characterized by the presence of pain, stiff-
ness, and limping which ultimately results with inability to perform activities 
of daily living. Thus, hip osteoarthritis significantly affects patients’ quality of 
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CE  – Center-Edge 
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CT  – Computed tomography 
DMOADs – Disease-modifying osteoarthritis drugs 
EULAR  – European League Against Rheumatism 
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GRO  – Growth-related oncogene 
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IL-6  – Interleukin-6 
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IL-17  – Interleukin-17 
IL-18  – Interleukin-18 
JSN  – Joint space narrowing 
K-L  – Kellgren-Lawrence 
LIF  – Leukemia inhibitory factor 
MCP-1  – Monocyte chemoattractant protein-1 
MRI  – Magnetic resonance imaging 
NIA  – National Institute on Aging 
NIAMS  – National Institute of Arthritis and Musculoskeletal and Skin Diseases 
OA  – Osteoarthritis 
OARSI  – Osteoarthritis Research Society International 
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life and represents a major public health problem. Because of 
its high incidence, prevalence and significant medical, social, 
and economic impact on society as a whole, in this review 
article we will describe and discuss terminology, classification, 
epidemiology, etiopathogenesis, clinical presentation, diagno-
sis, treatment, and prevention of hip osteoarthritis. 
INTRODUCTION
The hip joint, including the small joints of the hand and the knee, is one of the most commonly affected joints 
with osteoarthritis (OA) (1). Clinically, hip OA is character-
ized by fluctuating pain, crepitation, and decreased range 
of motion, which results with walking disability of the pa-
tient. The clinical features are generally associated with 
particular radiological changes of the hip joint. The latter 
are present in different stages of severity of OA comprising 
joint narrowing, subchondral bone sclerosis, bone cysts, 
and osteophytes formation. The aforementioned clinical 
and radiological features of hip OA consequently lead to 
patient disability in performing activities of daily living 
(ADL) and have a significant impact on their quality of life, 
which require treatment. Currently, there are three basic 
modalities of hip OA therapy: non-pharmacological, phar-
macological, and surgical (2). However, the contemporary 
efficiency of treatment is limited to pain relief, improve-
ment in mobility and performance of ADL, and attempts 
to repair damaged cartilage with cell-based therapies (3). 
Furthermore, current treatment regimens are only par-
tially effective, and that is the main reason for physician’s 
dissatisfaction in treating hip OA with such therapies.
Since the cause (etiology) of OA is still not fully eluci-
dated, the etiological treatment is not possible. Therefore, 
the main goal of treatment is to slow down, or at best, to 
halt disease progression. Numerous previous studies have 
improved our understanding of the causes, risk factors, 
pathophysiological pathways, and mechanisms responsi-
ble for the onset and progression of OA [for a review, see 
(4-8)]. A better understanding of the disease pathophysi-
ology will allow the identification of new therapeutic 
targets in the treatment of OA. However, there is a prob-
lem not only for patients with OA and doctors who treat 
such patients, but also for the society as a whole, due to 
inability to cope with the medical needs in finding ade-
quate treatment of this disease. So, one of the major chal-
lenges in the future will be to find the most appropriate 
treatment for OA, or a collection of very suitable thera-
peutic regimens that can perhaps border with goals of 
personalized medicine.
OSTEOARTHRITIS OR 
OSTEOARTHROSIS?
Genomic analysis of osteoarthritis renewed the debate 
about whether it is proper to call this disease osteoarthri-
tis or osteoarthrosis, due to semantic problems in the 
definition of inflammation present in cartilage (9, 10). 
Namely, the term osteoarthritis (suffix -itis is added to the 
root of the word) refers to the fact that this disease has an 
inflammatory component in the pathophysiological pro-
cess, unlike the term osteoarthrosis (suffix -osis is added 
to the root of the word), which points to the fact that a 
degenerative process is the dominant one. Thus, in the 
post-genomic era of molecular medicine, this issue is not 
just a question of semantics (that studies solely the mean-
ing of the word) (10), but also of synonymy (that studies 
semantic relationship between two lexemes belonging to 
the same type of a word, which have a different expression 
but hold the same content). In other words, are they simi-
lar terms, as it is often stated in literature (11)? In addition, 
it has been s suggested that the question referred to the 
name of this disease is actually a difference in expression 
in the Anglo-Saxon or German speaking area, justifying 
the interpretation by the appearance of disease symptoms 
as a result of dual (chemical and mechanical) action of 
joint cartilage detritus (12). For example, in German 
speaking countries, osteoarthrosis pathology will include 
the occurrence of synovitis (inflammation of the synovial 
membrane), which arises as a consequence of degenerative 
changes (e.g. shearing) of cartilage, whereas in the Anglo-
Saxon literature this disease is called osteoarthritis (13). 
The question is what is primary and what is secondary in 
osteoarthritis? Namely, if the inflammation in osteoar-
thritis occurs, does it contain all the classic signs of in-
flammation, according to the 20-century-old definition 
proposed by the Roman physician Cornelius Celsius, such 
as the presence of redness and swelling with warmth and 
pain (from the Latin rubor et tumor cum calore et dolor), 
or some of these signs do not manifest themselves in this 
disease (10, 14)? The answer was given by gene-expression 
analysis by chip-technology, which showed that avascular, 
alymphatic, and aneural human articular cartilage af-
fected by osteoarthritis (sometimes even before a stronger 
clinical manifestations of the disease) contains cells in 
cartilage like activated macrophages, which show super-
induction of inflammatory mediators, but without other 
signs of inflammation (10). Given the proven presence of 
inflammatory mediators, in the post-genomic era of mo-
lecular medicine, it has been proposed to call this disease 
osteoarthritis, rather than osteoarthrosis.
CLASSIFICATION
Although many classifications of OA exist, the most 
common one used in literature is that of the Subcommit-
tee on Classification Criteria of Osteoarthritis, a subcom-
mittee of the Diagnostic and Therapeutic Criteria Com-
mittee of the American Rheumatism Association from 
1986 (Table 1) (15). OA can be divided into primary and 
secondary. Primary OA is a disease of unknown etiology 
(but with pro-inflammatory character), which occurs in 
the elderly. Secondary OA occurs predominantly at a 
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younger age, and it is usually a consequence of other dis-
eases or conditions with a known cause such as develop-
mental disorders, trauma, or the like, which leads to the 
process also characterized by the appearance of inflam-
matory mediators (16).
EPIDEMIOLOGY
Epidemiological principles can be used to describe the 
distribution of OA in the population, and also to assess 
the impact of risk factors on the onset and progression of 
the disease (17). For the purposes of epidemiological re-
search, OA can be defined pathohistologically (18), radio-
logically (19), or clinically (15, 20). Radiological defini-
tion of OA has long been considered as the reference 
standard (17). In fact, there are several ways to define 
radiologically this disease (15, 19-24). The most common 
method for radiological definition of OA is the Kellgren-
Lawrence (K-L) grading scale for radiological assessment 
of OA (19) and atlas of individual radiographic features 
in OA (25). Other radiological measurements, including 
a semi-quantitative assessment of individual radiographic 
features (such as osteophytes and joint space narrowing 
[JSN]) or direct measurement of the distance between 
two bones that form a particular joint (as an indicator of 
joint space width in knees and hips), are used for the 
analysis of OA progression in epidemiological studies and 
in clinical trials of drugs that modify the course of the 
disease (disease-modifying osteoarthritis drugs – 
DMOADs) (26, 27). More sensitive imaging method for 
evaluating the severity of OA is the magnetic resonance 
imaging (MRI), by which one can visualize more struc-
tures within the joint, define different stages of OA, and 
detect potential DMOADs efficacy in much faster way 
than by conventional radiological techniques (21, 28).
Studies that examine the symptomatic OA may be 
more clinically relevant, because all patients with radio-
logically diagnosed OA do not have symptomatic OA, 
and vice versa, all patients with symptomatic OA need not 
necessarily have a potentially radiologically diagnosed one 
TAble 1
Classification of subsets of osteoarthritis (OA) [15].
I. Primary (idiopathic)
A. Localized
1.  Hands: nodal (Heberden’s and Bouchard’s nodes), non-
nodal (erosive IP arthritis), S-MC, S-T
2.  Feet: hallux valgus, hallux rigidus, hammer/cockup toes, 
talo-navicular joint
3.  Knee:
a. Medial compartment
b. Lateral compartment
c. Patellofemoral compartment
4.  Hip:
a. Eccentric (superior)
b. Concentric (axial, medial)
c. Diffuse (coxae senilis)
5. Spine (especially cervical and lumbar)
a. Apophyseal
b. Intervertebral (disc)
c. Spondylosis (osteophytes)
d. Ligamentous (hyperostosis [Forestier’s disease, or 
DISH])
6.  Other joints: shoulder, temporomandibular, sacroiliac, 
ankle, wrist, acromioclavicular
B. Generalized (includes 3 or more areas listed above)
1. Small (peripheral) and spine
2. Large (central) and spine
3. Mixed (peripheral and central) and spine
II. Secondary
A. Post-traumatic
B. Congenital or developmental diseases
1. Localized
a. Hip diseases: LCPD, DDH, SCFE, shallow acetabulum
b.  Mechanical and local factors: obesity, leg length in-
equality, extreme valgus/varus deformity, hypermobility 
syndromes, scoliosis
2. Generalized
a.  Bone dysplasias: epiphyseal dysplasia, spondylo-apophy-
seal dysplasia
b.  Metabolic diseases: hemochromatosis, ochronosis, Gau-
cher’s disease, hemoglobinopathy, Ehlers-Danlos disease
C. Calcium deposition disease
1. Calcium pyrophosphate deposition disease
2. Apatite arthropathy
3. Destructive arthropathy (shoulder, knee)
D.  Other bone and joint disorders: avascular necrosis, rheuma-
toid arthritis, gouty arthritis, septic arthritis, Paget’s disease, 
osteopetrosis, osteochondritis
E. Other diseases
1.  Endocrine diseases: diabetes mellitus, acromegaly, hypothy-
roidism, hyperparathyroidism
2. Neuropathic arthropathy (Charcot joints)
3. Miscellaneous: frostbite, Kashin-Beck disease, Caisson disease
Legend: DDH – Developmental Dysplasia of the Hip; DISH – Diffuse idiopathic skeletal hyperostosis; IP – Interphalangeal; LCPD – Legg–Calvé–
Perthes Disease; SCFE – Slipped Capital Femoral Epiphysis; S-MC – Scapho-metacarpal; S-T – Scapho-trapezial
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(29). Given this variability in assessing the diagnosis, each 
set of clinical and radiological criteria can differently de-
fine OA in the same person (29).
The prevalence and incidence of hip 
osteoarthritis
The prevalence (proportion of patients in the popula-
tion dependent on the incidence and duration of the dis-
ease) and incidence (number of new patients in relation 
to the number of vulnerable people that can become ill 
from particular disease within a certain population over 
a given period) of primary hip OA increases with age (30-
32). The prevalence of hip OA varies among the studies 
in relation to the definition of hip OA, but also according 
to the characteristics of the observed population in the 
study (17).
Radiologically diagnosed (radiographic) hip OA was 
less frequent in relation to radiographic hand or knee OA. 
For example, about 7% of women aged ≥ 65 years had 
radiographic hip OA in The Study of Osteoporotic Frac-
tures Research Group (33). However, the incidence of 
radiographic hip OA was much higher in The Johnston 
County Osteoarthritis Project, with 27% of respondents 
aged at least 45 years, showing radiological evidence of the 
severity of hip OA by K-L scale 2 or more (34). Possible 
explanation for the differences between those studies are 
differences in the observed populations, differences in the 
definition of OA, distribution of risk factors for the devel-
opment of OA, as well as differences among observers who 
assessed the degree of radiographic severity of OA (17).
Symptomatic OA is generally defined by the presence 
of pain and limited mobility of the affected joint with 
certain radiological characteristics (JSN, osteophytes, sub-
chondral cysts, and subchondral bone sclerosis), and in 
dependence of the degree of OA severity (17). The preva-
lence of symptomatic OA also increases with age (35). 
Specifically, about 9% of respondents in The Johnston 
County Osteoarthritis Project had symptomatic hip OA 
(34).
Oliveria et al. (31) in their study reported that the in-
cidence of symptomatic OA of the hip, knee and hand 
standardized by age and sex is 88, 240, and 100 per 100 
000 person yearly in subjects from the Massachusetts 
health maintenance organization. The incidence rate of 
symptomatic hand, knee or hip OA is rapidly growing 
around the age of 50, and the same is then equalized after 
70 years of age.
Risk factors for the development of hip 
osteoarthritis
Osteoarthritis has a multifactorial etiology. In addi-
tion, there are multiple genetic risk factors. The develop-
ment of OA can be seen as a result of the interaction be-
tween systemic and local risk factors (36). For example, a 
person may have inherited predisposition for the develop-
ment of OA, whereas the similar outcome can occur only 
if that person suffers an injury to a joint (17). The relative 
importance of risk factors may vary for different joints, 
for different stages of disease, for the development in rela-
tion to disease progression, and for the radiologically di-
agnosed OA in the relation with symptomatic OA (17). 
There is evidence that suggests that some risk factors may 
act independently according to some individual radio-
graphically-defined disease characteristics, such as osteo-
phytes and JSN (36).
Multiple risk factors exist for the development of pri-
mary hip OA, such as age, sex, ethnicity, obesity, occupa-
tional (37) and genetic factors for which are believed to 
be associated with the development and progression of 
this disease (38). All risk factors were classified into two 
groups: systemic and local.
Systemic risk factors for the 
development of hip osteoarthritis
Systemic risk factors for the development of hip OA 
include age, gender, hormones, race/ethnicity, genetics, 
congenital/developmental abnormalities, and nutrition.
Age is one of the strongest risk factors for the develop-
ment of OA in all joints including the hip (36, 39, 40). 
The increase in incidence and prevalence of OA with age 
increase was probably consequence of cumulative expo-
sure to various risk factors and biological changes that 
occur with aging (17). Those biological changes may de-
crease functional abilities of particular joint during the 
action of certain unfavorable circumstances, such as thin-
ning of the articular cartilage, muscle power loss, poor 
proprioception, and oxidative damage (17).
Women, not only have a possibility to develop OA more 
often than men, but also with a more severe form (41). 
Increased incidence of OA in women during menopause 
has prompted research on whether hormonal factors play 
a role in the occurrence of OA. However, the results of 
observational studies on the impact of endogenous or ex-
ogenous estrogen on the occurrence of OA are contradic-
tory (42-44). For example, in the Heart and Estrogen/
Progestin Replacement Study (HERS) (45), a randomized, 
double-blind, placebo-controlled trial, there was no sig-
nificant effect of 4 years of combined estrogen and proges-
tin hormone replacement therapy (HRT) compared with 
placebo on knee pain and related disability. On the con-
trary, data from the Women’s Health Initiative (46), pla-
cebo-controlled, double-blind, randomized trials have 
shown that women on estrogen-alone HRT have 15% less 
chance for total knee replacement (TKR) or total hip re-
placement (THR) surgery compared to those women with-
out such therapy. Additionally, combined estrogen and 
progestin HRT was not associated with the risk for TKR 
or THR surgery.
The prevalence of OA as well as localization of indi-
vidual joints affected by OA differs among racial and ethnic 
groups (17). Results from „The Johnston County Osteoar-
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thritis Project” showed that the prevalence of hip OA in 
African American women (23%) was similar to that of 
Caucasian women (22%), while the prevalence of OA of 
the same localization in males was slightly higher in Afri-
can Americans (21%) than in Caucasians (17%) (47). An 
interesting fact from the same study is that the prevalence 
of individual radiographic features of hip OA varied be-
tween African Americans and Caucasians. Namely, JSN in 
the upper part of the hip joint as well as the occurrence of 
osteophytes in the lateral part of the hip joint is more com-
mon in African Americans than in Caucasians. However, 
the racial/ethnic difference related to the anatomical varia-
tions of femoral head and acetabulum, could be an impor-
tant risk factor in radiographic hip OA in Caucasians (48, 
49), and this remains a problem for research in the future.
Numerous studies have demonstrated the importance 
of heredity for the development of primary OA, as well as 
heredity variation with regard to OA localization (50-55). 
Studies of monozygotic and dizygotic twins, as well as 
family studies have shown that hereditary component for 
the development of OA estimates ranging approximately 
from 50 and 65% with a greater genetic influence for the 
development of hand and hip OA than the knee OA (50-
52). Furthermore, MacGregor et al. (55) examined the 
genetic contribution to radiogarphic hip OA in women 
and concluded that the genetic factors have a significant 
contribution for the development of hip OA and account 
for approximately 60% of the variability in the population.
Some congenital or developmental disorders (such as 
developmental dysplasia of the hip, Legg-Calvé-Perthes 
disease, or slipped capital femoral epiphysis) are associated 
with the occurrence of hip OA later in life (56-58). Given 
the fact that previously mentioned disorders are rare, it can 
be assumed that they have little impact on the incidence of 
hip OA in the general population (17). Several studies have 
investigated the subclinical form of acetabular dysplasia 
(which was defined by values of Center-Edge (CE) angle of 
Wiberg ranging 20-25° in people without clinical symp-
toms in the hip joint), which is the common and milder 
form of developmental disorder of the hip, and its correla-
tion with the development of hip OA, with contradictory 
results (59-63). Lane et al. (59) in their study showed that 
the abnormal CE angle of Wiberg and acetabular dysplasia 
are associated with approximately threefold increased risk 
for early development of hip OA in women, suggesting that 
subclinical form of acetabular dysplasia could be a signifi-
cant risk factor for the development of hip OA.
Nutritional factors, which represent one of the sys-
temic risk factors for the development of OA, are the sub-
ject of great interest of researchers who seek to clarify their 
role in the development of OA. One of the dietary factors 
assumed to influence the development of OA is vitamin 
D. However, results of these studies are contradictory (64-
67). Namely, without the sufficient amounts of vitamin D 
in the body, bones can become thin, brittle, or deformed. 
In the Study of Osteoporotic Fractures Research Group 
(65), women with medium (23-29 ng/ml) and the lowest 
(8-22 ng/ml) levels of 25-vitamin D in serum are three 
times more likely to develop incident radiographic hip OA 
(defined by JSN) compared to women with the highest 
values (30-72 ng/ml) of this vitamin in the serum. Also, 
the same study has shown that low serum levels of 25-vi-
tamin D were not associated with risk for the development 
of osteophytic form of incident radiographic hip OA, and 
that serum levels of 1,25-vitamin D were not associated 
at all with radiographic changes of hip OA.
Local risk factors for the development 
of hip osteoarthritis
The local risk factors for the development of hip OA 
include overweight and obesity, previous injury and/or 
surgery, occupation, physical activity, and sport.
Obesity (body mass index [BMI] ≥30) and overweight 
(BMI 25.0-29.9) have been long time ago recognized as 
risk factors for the development of OA, particularly knee 
OA (36). However, the relationship between overweight 
and obesity with hip OA is inconsistent. If the impact on 
the development of hip OA exists, such a linkage is less 
pronounced than in patients with knee OA (68, 69). 
However, it was shown that obesity increases the risk for 
the development of bilateral radiographic, as well as 
symptomatic hip OA (70). In the study of Karlson et al. 
(71) it was observed that increased BMI (especially at the 
age of 18 years) is significantly associated with increased 
risk for THR. The increased joint loading is probably the 
main, but not the only mechanism by which obesity could 
cause knee or hip OA; namely, excessive loading of the 
knees and hips can lead to the joint damage with the 
concomitant loss of ligamentous and other structural sup-
port (17).
Previous injury and/or surgery of the hip joint can lead 
to increased incidence and earlier development of hip OA. 
Namely, in the study of Cooper et al. (72) it was observed 
that an increased incidence of hip OA occurs in a popula-
tion with a previous hip injury. Such hip injury is more 
associated with an earlier development of unilateral hip 
OA in men than in women. Furthermore, it was stated 
that time from the hip injury to the onset of symptoms 
(pain and limited mobility) is on average 13 years. There-
fore, the conclusion is that previous hip injury represents 
a risk factor for the development of hip OA.
Highly repeated overuse of joints in performing various 
work activities is associated with increased risk for the de-
velopment of OA (17). Explicitly, the increased risk for hip 
OA was observed in workers who frequently lift and carry 
heavy loads, such as construction workers and farmers 
(73). Also, there was a positive correlation between fre-
quent stair climbing during work activities and increased 
incidence for hip OA. On the other hand, increased inci-
dence of hip OA as a consequence of frequent ladder climb-
ing was not proven. With regard to the long-term kneeling 
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and squatting while performing work activities and hip 
OA, so far, there was also no established correlation.
Previous studies that have examined the relationship 
between sports activities and the consequent development 
of OA have yielded inconsistent results (17). However, 
there are indicators in the literature, which point to the 
fact that there is an increased risk for the development of 
hip OA in competitive long-distance runners (74, 75). 
Even more surprising is the fact that general physical ac-
tivity can also increase the risk for hip OA. For example, 
the study by Lane et al. (76) reported that women with 
higher than „normal” level of physical activity also had 
higher prevalence of hip OA.
In the introductory part of the subsection about factors 
for the development of hip OA, all risk factors were clas-
sified into two groups: systemic and local. However, what 
is important to emphasize, from the clinical perspective, 
is the fact that particular risk factors for the development 
of hip OA are modifiable, such as patient hormonal status, 
nutrition, overweight and obesity, preceding injury and/
or surgery, occupation, physical activity and sport. The 
remaining risk factors, such as age, sex, race/ethnicity, 
genetics and congenital/developmental abnormalities are 
non modifiable. Therapeutic action on modifiable factors 
can positively influence prevention of hip OA if risks were 
reduced.
Genetic epidemiology of hip 
osteoarthritis
Genetic epidemiology studies the genetic factors that 
determine the distribution and dynamics of particular 
disease in the population using different methods of 
analysis (77). With the advent of high-throughput geno-
typing, it has become possible to genotype (i.e. analyze 
variations of DNA sequences) over a million single nucle-
otide polymorphisms (SNPs) per person and genotyping 
dozens or thousands of people in a single study (78). The 
previously mentioned arguments, and the fact that cur-
rent SNP markers cover over 85% of the genome in the 
Caucasian population (79), mean that access to associa-
tion analysis of the genome has the potential to reveal the 
genetic contribution in complex human diseases such as 
osteoarthritis (78). Etiological insights that might stem 
from such research should lead to improved diagnostic 
TAble 2
List of selected epidemiological studies of osteoarthritis in the period from 1941. – 2000.
Ordinal number Geographical origin Osteoarthritis localization
1 USA Hand OA
2 USA Hand OA
3 UK Hand OA
4 UK Hand OA
5 UK Generalized OA
6 UK Generalized OA
7 UK Generalized OA
8 USA Generalized OA (Hand and knee OA)
9 UK Generalized OA (Hand and knee OA)
10 Sweden Hip OA
11 UK Knee and hip OA 
12 UK Hip OA
13 Iceland Hip OA
14 USA Spine OA
15 Japan Spine OA
16 Italy Spine OA
17 USA Spine OA
18 UK Hand and knee OA
19 UK Cervical and lumbar spine OA
20 UK Hip OA
Legend: OA – Osteoarthritis, UK – United Kingdom; USA – United States of America.
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and prognostic capabilities and enable the development 
of more specific therapies for osteoarthritis of large joints.
One of the earliest indications that genetic predisposi-
tion for the development of OA exists has been known 
since 1941 (Table 2, Study under ordinal number) (80). 
Namely, Stecher noticed frequent occurrence of Heberden 
nodes (spindle thickening of the hand distal interphalan-
geal joints) in particular families. In its work, Stecher 
concludes that this phenotype is inherited as a dominant 
trait with a strong preponderance in favor of the female 
sex, and sets the concept that the OA is the hereditary 
disease. Further family studies (Table 2, studies under 
ordinal numbers 2-7) have shown that the nodal OA (sud-
den appearance of swelling, pain and redness in the area 
of  the distal interphalangeal joints of the hands in women 
older than 45 years) often occurs as part of generalized 
OA and, based on the results of those studies, it has been 
proposed polygenic inheritance for OA, defining thus OA 
as a complex (polygenic) disease (81-86).
To confirm the role of different genes in the develop-
ment of OA, further epidemiological studies were con-
ducted (Table 2, studies under ordinal numbers 8-17) (52, 
87-95). Those studies included families with frequent oc-
currence of hand, knee, hip and spine OA. The results of 
these studies confirmed the significant impact of heritage 
in the development of OA. However, epidemiological 
studies usually have two basic weaknesses: insufficient 
data and the possibility that on the risk for the develop-
ment of OA may affect environmental factors which are 
unknown, unrecorded, or are difficult to verify because 
they are obtained from patient medical history (e.g. pa-
tient occupation, etc.).
For these reasons, the genetic background for the de-
velopment of potentially hereditary diseases (in this case 
OA) can be proved with twin studies (Table 2, studies 
under ordinal numbers 18-20) (51, 55, 96). These studies 
compare the frequency of disease occurrence between 
monozygotic and dizygotic twins. Namely, as monozy-
gotic twins share 100% of their genetic material, observed 
concordance in the incidence of disease directly shows the 
level of influence of genetic risk on the development of 
such diseases. Based on this, risk for the development of 
such disease is calculated and compared to the observed 
concordance in dizygotic twins, which share only 50% of 
their genetic material. The results of these studies have 
shown, after the correction with known confounding fac-
tors (such as obesity, occupation, sports activity, etc.), that 
development of 60% radiographic hip OA in women can 
be attributed to genetic factors independent of known 
predisposing (environmental or demographic) factors (78).
There are several possible strategies that can be used to 
investigate the role of genetics in the development of hip 
OA, such as: family studies, twin studies, candidate gene 
studies, genome-wide association studies (GWAS), and 
meta-analyzes (78, 97-102). Due to the facts that extensive 
literature exists regarding the role of genetics in the devel-
opment of hip OA (using previously listed strategies) and 
its extent is beyond the scope of this subsection, we refer 
the reader to the additional literature regarding this topic.
Previous studies regarding genetic predisposition for 
the development of hip OA in the Croatian population 
(103, 104), carried out in multicentre collaboration (Uni-
versity Hospital for Orthopaedics and Traumatology 
Lovran, School of Medicine, University of Rijeka, Croa-
tia; Department of Physiology and Immunology, School 
TAbliCA 3
Clinical criteria for the diagnosis of hip osteoar-
thritis (OA) (20).
Traditional criteria
Hip pain in the presence of one of the following criteria:
– ESR <20mm/hour
– radiographic femoral or acetabular osteophytes
– radiographic JSN (superior, axial, and/or medial) 
The criteria according to the classification tree
Hip pain and radiographic femoral and/or acetabular 
osteophytes
or
Hip pain with radiographic axial JSN and ESR ≤20mm/hour
Legend: ESR – Erythrocyte sedimentation rate; JSN – Joint 
space narrowing.
TAble 4
Kellgren-Lawrence grading scale for radiological assessment of osteoarthritis (OA) (19).
Radiographic 
grade
0 I II III IV
Classification Normal Doubtful Mild Moderate Severe
Description –  no radiographic 
features
–  minute osteophytes
–  doubtful significance
–  definite ostephytes
–  normal joint space
–  definite ostephytes
–  moderate joint space 
narrowing
–  definite ostephytes
–  severe joint space  
narrowing
–  subchondral sclerosis
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of Medicine, University of Rijeka, Croatia; Clinical In-
stitute for Transfusion Medicine, University Hospital 
Center Rijeka, School of Medicine, University of Rijeka, 
Croatia; Department of Oral Biology, Molecular Genet-
ics Laboratory, University of Oslo, Norway) showed that 
1-1-1-2 haplotype of the interleukin-1 (IL1) gene locus 
could be associated with a predisposition for the develop-
ment of hip OA (104). Our results corroborate the pub-
lished studies in a German (105), Dutch (106), and UK 
(107, 108) population, in which haplotype 1-1-1-2 has 
been found to be associated with susceptibility to hip OA. 
On contrary, our study contradicts a latter UK study 
(109) which described lack of association with susceptibil-
ity to hip OA in persons with 1-1-1-2 haplotype. Possible 
explanations for such contradictory outcomes between 
our and other published association studies regarding 
susceptibility to hip OA could be the differences in com-
plex inheritance variability and environmental exposures 
in diverse populations. Our further research (110) has 
shown the connection between variable number tandem 
repeat (VNTR) polymorphism in the second exon of the 
family with sequence similarity 46, member A (FAM46A) 
gene and BCL2-associated athanogene 6 (BAG6) gene 
rs3117582 SNP with predisposition for the development 
of the large joint (hip and knee) OA in the same popula-
tion. In conclusion, aforementioned results show that the 
IL1 gene locus, as well as FAM46A and BAG6 genes in 
„collaboration“ with some unknown gender-specific fac-
tors, not excluding other genetic or epigenetic factors, are 
involved in the pathogenesis of primary hip OA.
ETIOPATHOGENESIS
The last and still valid definition of osteoarthritis is the 
one from 1995 (111), established by consensus of experts 
in the area of  this disease from the American Academy of 
TAble 5
Guidelines of non-surgical (non-pharmacological 
and pharmacological) and surgical treatment of 
hip osteoarthritis (OA).
Non-pharmacological treatment
It is recommended that patients do the following:
–  cardiovascular (aerobic) and/or resistance exercise
–  exercise in water
–  body weight reduction (for obese)
It is conditionally recommended that patients do the following:
–  participation in programs of self-medication
–  manual therapy in combination with a controlled exercises
–  psychosocial support
–  instruct patients about local heat application
–  use of walking aids (if needed)
No recommendation regarding the following:
–  participation in balance exercises or in combined balance and 
strength exercises
–  participation in tai chi programs
–  application of manual therapy as the only treatment
Pharmacological treatment
It is conditionally recommended that patients should use one of the  
following:
–  paracetamol
–  oral NSAIDs
–  tramadol
–  IA corticosteroid injections
It is conditionally recommended that patients should not use the following:
–  chondroitin sulfate
–  glucosamine
There is no recommendation regarding the use of the following:
–  topical NSAIDs
–  IA hyaluronate injections
–  duloxetine
–  opioid analgesics
Surgical treatment
Depending on the severity of OA:
–  hip arthroscopy
–  open hip debridement
–  osteotomies around hip joint (pelvic and/or proximal femoral 
osteotomies)
–  total hip replacement
Legend: IA – Intra-articular; NSAIDs – Non-steroidal anti-inflam-
matory drugs.
Figure 1. Antero-posterior X-ray of the pelvis and both hips showing 
advanced bilateral hip osteoarthritis with the presence of classical 
radiographic findings, such as joint space narrowing, subchondral 
sclerosis, osteophytes, and subchondral cysts.
Orthopaedic Surgeons (AAOS), National Institute of Ar-
thritis and Musculoskeletal and Skin Diseases (NIAMS), 
National Institute on Aging (NIA), Arthritis Foundation, 
and the Orthopaedic Research and Education Founda-
tion (OREF), which reads as follows:
„Osteoarthritis (OA) represents a group of different 
overlapping diseases that can have various causes, but 
similar biological, morphological and clinical outcome. 
The pathophysiological process in this disease affects not 
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only the joint cartilage, but involves the whole joint in-
cluding subchondral bone, ligaments, joint capsule, syno-
vial membrane and periarticular muscles. Finally, degen-
eration of articular cartilage occurs with fibrillation, 
fissures, and ulceration, which ultimately leads to loss of 
full cartilage thickness up to the subchondral bone. OA 
is a result of interaction of mechanical and biological 
events that destabilize the equilibrium of degradation and 
synthesis of chondrocytes and extracellular matrix of the 
articular cartilage, as well as subchondral bone. Several 
factors, such as genetic, developmental, metabolic, and 
traumatic lead to initiation of this disease. Changes dur-
ing OA affect all tissues of the diarthrodial joints. In its 
final stage, OA is manifested by morphological, biochem-
ical, molecular, and biomechanical changes of cells and 
matrix which lead to a softening, fibrillation, ulceration 
and loss of joint cartilage, sclerosis and eburnation of the 
subchondral bone, formation of osteophytes and sub-
chondral cysts. When it becomes clinically evident, OA 
is manifested by pain, tenderness, limited range of move-
ment, crepitus and occasional swelling of the affected 
joint, as well with a variable degree of inflammation with-
out systemic effects.“
According to Brandt et al. (112) this inclusive defini-
tion offers something for everyone, but is not helpful in 
understanding the etiopathogenesis of OA. OA is the 
most common disease of the musculoskeletal system in 
middle and old age in developed countries (113). There-
fore, it is of particular importance to study pathogenesis, 
clinical aspects and treatment of this disease, because it 
has a high incidence, prevalence and significant medical, 
social and economic impact on society. The etiology of 
OA is still unclear, and thus the etiological treatment of 
this disease is not possible. Given the fact that the etiol-
ogy of OA remains unclear, the main goal of treatment is 
to slow down, or at best, halt progression of OA (2).
Numerous previous studies have improved our under-
standing about the causes, risk factors, pathophysiological 
pathways, and mechanisms responsible for the onset and 
progression of OA (2). If we talk about the molecular 
pathogenesis of OA, this disease affects the whole joint 
(114). Namely, the cartilage, synovial membrane, and 
bone may be the main place of production of cytokines, 
growth factors, chemokines, and inflammatory mediators 
that promote the occurrence of inflammation and pro-
gressive destruction of joints affected by OA (115, 116). 
Joint destruction affected by OA is primarily character-
ized by the destruction of cartilage as a result of, at first, 
subclinical inflammatory changes in the cartilage detect-
able only at the molecular level (10, 115). Abnormal me-
chanical loading seems to „wake up“ chondrocytes from 
the state of low metabolic activity (117) and stimulates 
these cells to produce proinflammatory mediators, many 
of which are produced by macrophages during the re-
sponse to injury or infection (10). These inflammatory 
mediators include numerous cytokines and chemokines 
such as interleukin-1 (IL-1), IL-6, IL-8, IL-17, IL-18, 
monocyte chemoattractant protein-1 (MCP-1), leukemia 
inhibitory factor (LIF), growth-related oncogene (GRO) 
and oncostatin M (OSM), as well as reactive oxygen spe-
cies (ROS) such as nitric oxide, superoxide, hydrogen 
peroxide and peroxynitrite (116). All previously men-
tioned mediators of inflammation along with derivatives 
of arachidonic acid (prostaglandins and leukotrienes) in-
crease catabolic activity of chondrocytes, which results in 
production and release of a number of proteolytic en-
zymes, including matrix metalloproteinases and aggreca-
nase, leading to degradation of the cartilage matrix (116).
Finally, the research should be directed at better un-
derstanding of the etiology and pathophysiology of this 
disease in the future, which will eventually allow the iden-
tification of new therapeutic targets and successful treat-
ment of patients with OA.
CLINICAL PRESENTATION
Discomforts related to the occurrence of OA are de-
scribed as the presence of symptoms and signs of the dis-
ease in certain patients whose joint (or joints) is affected 
by osteoarthritis. Symptoms of the disease are defined as 
the subjective experience of the patients, while signs of the 
disease are objective indicator of certain diseases. Symp-
toms of OA is the cause that bring the patient to the 
physician, and the physician observes signs of OA upon 
examining patients with OA of particular joint (or joints).
The most common symptoms of the disease associated 
with the occurrence of OA are pain in the affected joint, 
morning stiffness of the joint that lasts up to 30 minutes, 
instability or deformity of the joint, and limited joint 
function or loss of joint function (118).
The most common signs of the disease associated with 
the occurrence of OA in the affected joint are bone prom-
inence, limited or blocked joint mobility, crepitus and/or 
pain during movement, and malalignment (incorrect po-
sitioning of bones of the joint) and/or deformity of the 
joint (118).
The most common symptom of hip OA is the appear-
ance of pain in the hip joint. Usually such pain develops 
gradually, in the beginning it is of lower intensity and 
intermittent, but over time became much more severe and 
more frequent. However, sudden onset of pain was de-
scribed in the patients with hip OA (118). Pain and stiff-
ness of the hip joint can be more pronounced in the morn-
ing or after a long sitting (20). Over time, painful episodes 
become more frequent and occur during sleep or during 
the night. Additional symptoms and signs of the disease 
that can occur in patients with hip OA are pain in the 
groin or thigh extending in the ipsilateral gluteal region 
or knee, pain that worsens with activity of daily living, 
limited range of movement (ROM) of the hip joint which 
hinders the patient mobility, blockages in the area of  the 
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hip joint (because of the presence of intra-articular loose 
bodies) with crepitus (due to wear of the cartilage), lim-
ited active and passive hip motion (especially internal 
rotation – it is usually earliest affected movement in the 
patient with hip OA!) that affects the mobility of hip and 
leads to limping and disturbed dynamics of walking, as 
well as aggravation of described symptoms during chang-
es in weather conditions (20, 118).
At the physical examination of patient with hip OA, 
one should pay attention to dynamics of the walking and 
the presence or absence of a limp from affected hip. In the 
area of the hip affected by OA tenderness and pain that 
increases during hip mobility is usually present. Simi-
larly, during examination of affected hip ROM, limited 
and painful active and passive mobility is also usually 
observed (20). Namely, the passive internal rotation is the 
most painful and the most limited movement in the hip 
joint (20). Moreover, crepitus can occur during the move-
ment in the hip joint.
DIAGNOSIS
All patients with OA of certain joint (or joints) can be 
classified into two groups: 1) patients with radiographic 
OA who are asymptomatic and are discovered inciden-
tally on the basis of radiographic imaging findings of af-
fected joint(s), and 2) patients with symptomatic OA, 
whose complaints, such as pain, restricted mobility and a 
reduction or loss of function of the affected joint(s), brings 
them to the physician. Symptomatic OA, as mentioned 
above, is generally defined by the presence of pain and 
limited joint(s) mobility with certain radiological charac-
teristics (e.g. JSN, osteophytes, subchondral cysts, and 
subchondral bone sclerosis), depending on the degree of 
the severity of OA (17).
The diagnosis of hip osteoarthritis is made on the basis 
of medical history, clinical presentation, physical exami-
nation, as well as basic and (if necessary) additional diag-
nostic imaging techniques. The most commonly used 
clinical criteria for the diagnosis of hip OA are the criteria 
of the American College of Rheumatology for the diag-
nosis and classification of hip OA (Table 3) (20).
Basic diagnostic imaging techniques for patients with 
suspected hip OA includes antero-posterior (AP) X-ray of 
pelvis with both hips (Figure 1) and axial X-rays of the 
pelvis with both hips („Frog-leg position“) (119). The most 
commonly used radiological criteria for the diagnosis of 
hip OA is Kellgren-Lawrence scale for radiological assess-
ment of OA (Table 4) (19). In the case of initial osteoar-
thritic changes in the hip with uncertain signs of OA 
(radiographic stage I according to K-L scale) additional 
diagnostic imaging techniques are indicated, such as ul-
trasound, computed tomography (CT), bone scan, or 
MRI of the hip (the most sensitive and most specific of 
all additional diagnostic imaging techniques) (120).
TREATMENT
Current modalities for the treatment of osteoarthritis, 
such as a non-surgical (non-pharmacological and phar-
macological) or surgical treatment do not cure the cause, 
but the consequences of OA (such as pain and loss of 
function) (121). To date, numerous guidelines for the 
treatment of OA have been described in literature. The 
table 5 shows a synthesis of recent published guidelines 
for non-surgical (non-pharmacological and pharmaco-
logical) and surgical treatments of hip OA from The Eu-
ropean League Against Rheumatism (EULAR) (122), 
The Osteoarthritis Research Society International (OAR-
SI) (123), American College of Rheumatology (ACR) 
(124), and Croatian Society for Rheumatology (CSR) 
(125).
Treatment of patients with hip OA depends on inten-
sity of symptoms, limitation of hip mobility, degree of 
disability in activities of daily living, and sleep disorders. 
The use of non-surgical (non-pharmacological and phar-
macological) treatment is always indicated in the initial 
stages of the disease. In advanced stages of the disease, 
when applied non-surgical treatment did not give satisfac-
tory results, surgical treatment of patients with hip OA is 
indicated. Total hip replacement surgery should be ap-
plied as the last method of treatment in patients with hip 
OA, i.e. after the failure or inability to use (due to the 
severity of the disease) all remaining methods of treat-
ments.
PREVENTION
Osteoarthritis, as the most common disease of the 
musculoskeletal system today, has significant social, eco-
nomic, and medical impact on society as a whole (2). 
Preventive strategies to reduce the impact and burden of 
the society by OA should be aimed at potentially modifi-
able risk factors in order to reduce their frequency. Reduc-
ing the risk for the development of OA is most effective 
when risk factors are modified in the risk population (39).
When considering preventive possibilities, evaluation 
of risk factors for the development and progression of OA 
is of great importance. Age is the strongest predictor for 
the development and progression of radiographic OA. In 
a population at risk for the development of OA are persons 
aged 50 years and those who are obese, with abnormal 
joint biomechanics, or with previous joint damage (126).
Prevention strategies that are recommended in patients 
with OA (and this also applies to the patients with hip 
OA) are education, elimination of unhealthy behaviors 
and promoting healthy habits, weight reduction, preserva-
tion of function of the affected joint(s), psychosocial sup-
port, treatment of comorbidities, rehabilitation measures, 
reducing the discomforts with self-medication (pharma-
cological interventions), and well-timed referral to surgi-
cal intervention (126).
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